Lipum lands $50.5K Vinnova grant to build biomarker strategy for RA drug
What's the deal? Swedish biotech Lipum has secured US$60.4K from VinnovaDealroom has a profile for this one. Try Dealroom →, the Swedish innovation agency, for a Swedish-German collaboration with Clairvoyant Diagnostics. The money will fund a biomarker strategy for SOL-116, Lipum's antibody candidate for rheumatoid arthritis.
Why now? The grant, announced in late September, lands as Lipum prepares for a phase IIa proof-of-concept trial. The goal is to stratify patients and read treatment response more precisely, using rheumatoid arthritis as the model indication.
What's the endgame? SOL-116 targets the enzyme BSSL in rheumatoid arthritis, a disease affecting roughly 1% of the world's population. The antibody aims to reduce inflammation while preserving normal immune function — a more targeted approach than many current therapies.
The bigger picture: The Vinnova award is modest, but it follows a run of larger milestones. Lipum leads a consortium set to receive about €8 million in non-dilutive Horizon EuropeDealroom has a profile for this one. Try Dealroom → funding for the phase IIa study, and its phase I results were published in RMD Open in July, confirming a favourable safety profile and target engagement.
CEO Ola Sandborgh told BioStock the company's position is "considerably more positive" than a year ago, citing the Horizon grant and Lipum's March 2026 merger with major shareholder Flerie, which took the company private.
What's next? Lipum expects to contract a CRO in October. The proof-of-concept study is scheduled to begin in early 2027, with topline data due in autumn 2028.
The signal: At roughly $50,500, this is a small grant — well below the scale of a typical venture round — but it reflects a deliberate, non-dilutive financing strategy at a value-critical clinical stage. The biomarker work supports SOL-116's path to patients without burning equity; the phase IIa trial will still need to show efficacy, not just safety.
Read more: biostock.se
Image credit: Generated with Gemini
